ArticleInternational journal of radiation oncology, biology, physics2015
Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.
Article in International journal of radiation oncology, biology, physics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.
- Electron FLASH radiotherapy in vivo studies. A systematic review.Frontiers in oncology · 2024Pooled it
- Consensus radiation therapy organ at risk constraints for NCTN trials in hematologic malignancies.Journal of the National Cancer Institute · 2026Article
- Combined application of block and modulation factors to reduce the volume of the low dose area in helical tomotherapy plans for lung cancer.Journal of applied clinical medical physics · 2025Article
- Association of SIRT6 Expression With Risk of Pneumonitis Induced by Radiotherapy in Cancer Patients.Molecular carcinogenesis · 2025Article
- The role of cGAS-STING pathway in the development of radiation-induced lung injury.Journal of cancer research and clinical oncology · 2025Article
- Development of a predictive model for radiation pneumonitis based on plasma exosomal miR-200b-5p.Frontiers in oncology · 2025Article
- Ultra-Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the Lung.Advances in radiation oncology · 2024Article
- Radiomics approach for identifying radiation-induced normal tissue toxicity in the lung.Scientific reports · 2024Article
- Article
- Dual-energy computed tomography in the early evaluation of acute radiation pneumonia.European journal of medical research · 2024Article
- Total body irradiation delivered using a dedicated Co-60 TBI unit: Evaluation of dosimetric uniformity and dose verification.Journal of applied clinical medical physics · 2024Article
- Radiation pneumonia predictive model for radiotherapy in esophageal carcinoma patients.BMC cancer · 2023Article
- Analysis of clinical and physical dosimetric factors that determine the outcome of severe acute radiation pneumonitis in lung cancer patients.Radiation oncology (London, England) · 2023Article
- Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy.Journal of translational medicine · 2023Review
- Microarray analysis of hub genes, non-coding RNAs and pathways in lung after whole body irradiation in a mouse model.International journal of radiation biology · 2023Article
- Quantitative Assessment and Comparative Analysis of Longitudinal Lung CT Scans of Chest-Irradiated Nonhuman Primates.Radiation research · 2023Article
- Risk analysis of grade ≥ 2 radiation pneumonitis based on radiotherapy timeline in stage III/IV non-small cell lung cancer treated with volumetric modulated arc therapy: a retrospective study.BMC pulmonary medicine · 2022Article
- IntegratingThoracic cancer · 2022Article
- Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection.International journal of radiation oncology, biology, physics · 2022Article
- Planning evaluation of a novel volume-based algorithm for personalized optimization of lung dose in VMAT for esophageal cancer.Scientific reports · 2022Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 1 institution in 1 country.
Funding
Abstract
purposeFew studies to date have evaluated factors associated with the development of radiation pneumonitis (RP) in patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), especially in patients treated with contemporary radiation techniques. These patients represent a unique group owing to the often large radiation target volumes within the mediastinum and to the potential to receive several lines of chemotherapy that add to pulmonary toxicity for relapsed or refractory disease. Our objective was to determine the incidence and clinical and dosimetric risk factors associated with RP in lymphoma patients treated with intensity modulated radiation therapy (IMRT) at a single institution. METHODS AND MATERIALS: We retrospectively reviewed clinical charts and radiation records of 150 consecutive patients who received mediastinal IMRT for HL and NHL from 2009 through 2013. Clinical and dosimetric predictors associated with RP according to Radiation Therapy Oncology Group (RTOG) acute toxicity criteria were identified in univariate analysis using the Pearson χ(2) test and logistic multivariate regression.
resultsMediastinal radiation was administered as consolidation therapy in 110 patients with newly diagnosed HL or NHL and in 40 patients with relapsed or refractory disease. The overall incidence of RP (RTOG grades 1-3) was 14% in the entire cohort. Risk of RP was increased for patients who received radiation for relapsed or refractory disease (25%) versus those who received consolidation therapy (10%, P=.019). Several dosimetric parameters predicted RP, including mean lung dose of >13.5 Gy, V20 of >30%, V15 of >35%, V10 of >40%, and V5 of >55%. The likelihood ratio χ(2) value was highest for V5 >55% (χ(2) = 19.37).
conclusionsIn using IMRT to treat mediastinal lymphoma, all dosimetric parameters predicted RP, although small doses to large volumes of lung had the greatest influence. Patients with relapsed or refractory lymphoma who received salvage chemotherapy and hematopoietic stem cell transplantation were at higher risk for symptomatic RP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.